Holder Michael 4

What Happened

• Michael, a director of Cytek Biosciences (CTKB), had 2,908 restricted stock units (RSUs) convert to common shares on March 10, 2026 (reported under transaction code M — exercise/conversion of a derivative). The filing shows an acquisition of 2,908 shares via conversion and a simultaneous disposition of 2,908 shares at $0.00 — indicating those shares were withheld to satisfy tax withholding. No cash proceeds were reported and the net issued shares to the insider from this event is effectively zero.

Key Details

• Transaction date: 2026-03-10 (reported on Form 4 filed 2026-03-12 — appears filed timely).
• Acquired: 2,908 shares via conversion of RSUs (price N/A per filing).
• Disposed: 2,908 shares at $0.00 (shares withheld for tax withholding/compensation-related disposition).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 clarifies an RSU represents a contingent right to one share. F2 provides the vesting schedule (portions vest on specified dates — e.g., 2/36 on Aug 18, 2024; 3/36 on Nov 18, 2024 and each Nov 18 thereafter; 4/36 on Mar 10, 2025 and each Mar 10 thereafter; plus additional tranches on May 18 and Aug 18 as listed).
• Transaction code: M (exercise or conversion of a derivative instrument); disposition code indicates tax withholding (not an open-market sale).

Context

• This was a routine compensation event: RSUs vested and converted to shares, and an equal number of shares were withheld to cover taxes. A disposition at $0.00 typically means shares were surrendered to the company for withholding and not sold in the market, so it does not reflect a decision to sell for cash. Purchases or open-market sales by insiders are generally more informative about sentiment; this filing documents standard vesting and tax withholding.